Instituto Rosenbusch S.A.

BA:ROSE Argentina Drug Manufacturers - Specialty & Generic
Market Cap
$7.86 Million
AR$8.18 Billion ARS
Market Cap Rank
#34943 Global
#61 in Argentina
Share Price
AR$192.00
Change (1 day)
-7.69%
52-Week Range
AR$83.90 - AR$380.00
All Time High
AR$380.00
Categories
Companies in Argentina Drug Manufacturers - Specialty & Generic
About

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more

Instituto Rosenbusch S.A. (ROSE) - Net Assets

Latest net assets as of September 2025: AR$635.55 Million ARS

Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) has net assets worth AR$635.55 Million ARS as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AR$8.09 Billion) and total liabilities (AR$7.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AR$635.55 Million
% of Total Assets 7.86%
Annual Growth Rate 25.97%
5-Year Change 1953.66%
10-Year Change 4194.98%
Growth Volatility 205.54

Instituto Rosenbusch S.A. - Net Assets Trend (2000–2024)

This chart illustrates how Instituto Rosenbusch S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Instituto Rosenbusch S.A. (2000–2024)

The table below shows the annual net assets of Instituto Rosenbusch S.A. from 2000 to 2024.

Year Net Assets Change
2024-12-31 AR$3.03 Billion -33.30%
2023-12-31 AR$4.55 Billion +1035.45%
2022-12-31 AR$400.51 Million +101.07%
2021-12-31 AR$199.19 Million +34.87%
2020-12-31 AR$147.69 Million +27.86%
2019-12-31 AR$115.52 Million -20.85%
2018-12-31 AR$145.95 Million +68.58%
2017-12-31 AR$86.58 Million +4.01%
2016-12-31 AR$83.24 Million +17.86%
2015-12-31 AR$70.62 Million +3.48%
2014-12-31 AR$68.24 Million +18.37%
2013-12-31 AR$57.65 Million -12.49%
2012-12-31 AR$65.88 Million +17.13%
2011-12-31 AR$56.25 Million +12.05%
2010-12-31 AR$50.20 Million +6.93%
2009-12-31 AR$46.95 Million +2.85%
2008-12-31 AR$45.65 Million +21.73%
2007-12-31 AR$37.50 Million +4.25%
2006-12-31 AR$35.97 Million +5.37%
2005-12-31 AR$34.13 Million +12.26%
2004-12-31 AR$30.41 Million +7.58%
2003-12-31 AR$28.27 Million +16.96%
2002-12-31 AR$24.17 Million +91.96%
2001-12-31 AR$12.59 Million +5.80%
2000-12-31 AR$11.90 Million --

Equity Component Analysis

This analysis shows how different components contribute to Instituto Rosenbusch S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 109309.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Other Components AR$6.11 Billion 214.88%
Total Equity AR$2.84 Billion 100.00%

Instituto Rosenbusch S.A. Competitors by Market Cap

The table below lists competitors of Instituto Rosenbusch S.A. ranked by their market capitalization.

Company Market Cap
MARKETAXESS HOLDING
MU:MWI
 		$1.57 Million
ALUMINIUM DU MAROC
BC:ALUMINIUM-DU-MAROC
 		$1.57 Million
NICE CALL PUBLIC COMPANY LIMITED
BK:NCP
 		$1.57 Million
OXFORD BIODYNAMICS LS-01
F:LMQ
 		$1.57 Million
Panbela Therapeutics Inc
NASDAQ:PBLA
 		$1.57 Million
Dalrada Financial Corp
PINK:DFCO
 		$1.57 Million
Gossan Resources Ltd
V:GSS
 		$1.57 Million
Agentix Corp
PINK:AGTX
 		$1.57 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Instituto Rosenbusch S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 4,169,037,012 to 2,842,422,814, a change of -1,326,614,198 (-31.8%).
  • Net loss of 1,417,322,392 reduced equity.
  • Other factors increased equity by 90,708,194.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income AR$-1.42 Billion -49.86%
Other Changes AR$90.71 Million +3.19%
Total Change AR$- -31.82%

Book Value vs Market Value Analysis

This analysis compares Instituto Rosenbusch S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.88x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 106.05x to 2.88x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 AR$1.81 AR$192.00 x
2018-12-31 AR$3.00 AR$192.00 x
2019-12-31 AR$2.46 AR$192.00 x
2020-12-31 AR$3.06 AR$192.00 x
2021-12-31 AR$4.16 AR$192.00 x
2022-12-31 AR$8.52 AR$192.00 x
2023-12-31 AR$97.89 AR$192.00 x
2024-12-31 AR$66.74 AR$192.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Instituto Rosenbusch S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -49.86%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -17.13%
  • • Asset Turnover: 1.10x
  • • Equity Multiplier: 2.65x
  • Recent ROE (-49.86%) is below the historical average (-0.47%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 8.43% 12.27% 0.56x 1.24x AR$-186.90K
2001 4.87% 6.96% 0.57x 1.22x AR$-645.90K
2003 12.52% 11.66% 0.85x 1.26x AR$713.50K
2004 8.30% 5.79% 1.11x 1.29x AR$-516.80K
2005 12.18% 7.66% 1.19x 1.33x AR$743.50K
2006 11.40% 6.12% 1.38x 1.35x AR$503.20K
2007 4.80% 2.36% 1.40x 1.45x AR$-1.93 Million
2009 2.13% 1.67% 0.91x 1.40x AR$-3.62 Million
2010 6.02% 5.19% 0.77x 1.50x AR$-1.95 Million
2011 10.56% 8.00% 0.83x 1.60x AR$306.90K
2012 14.54% 11.20% 0.72x 1.80x AR$2.90 Million
2014 13.04% 7.75% 0.76x 2.20x AR$1.94 Million
2015 -1.13% -0.54% 0.82x 2.57x AR$-7.19 Million
2016 13.42% 6.07% 0.85x 2.61x AR$2.59 Million
2017 -0.09% -0.04% 0.81x 2.77x AR$-7.78 Million
2018 0.62% 0.27% 0.82x 2.87x AR$-11.97 Million
2019 -85.11% -21.66% 0.83x 4.74x AR$-99.69 Million
2020 -13.07% -3.04% 0.83x 5.19x AR$-30.02 Million
2021 -11.06% -2.50% 1.05x 4.22x AR$-37.27 Million
2022 -2.23% -0.59% 1.02x 3.72x AR$-44.38 Million
2023 29.40% 12.43% 0.90x 2.63x AR$808.98 Million
2024 -49.86% -17.13% 1.10x 2.65x AR$-1.70 Billion

Industry Comparison

This section compares Instituto Rosenbusch S.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,110,930,148
  • Average return on equity (ROE) among peers: -19.41%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Instituto Rosenbusch S.A. (ROSE) AR$635.55 Million 8.43% 11.72x $1.57 Million
Laboratorios Richmond SACIF (RICH) $1.11 Billion -19.41% 1.44x $24.99 Million